RE:Wow Twisting the truth?
Seeking Alpha article:
While an outcome trial will unlikely be needed for a hypertriglyceridemia label, subsequent uptake in the marketplace likely will. During the 2020 Q2 conference call, ACST management had indicated that the likelihood of an outcomes trial was high.
Jan D’Alvise
Yes. Thanks, Leland. So let me respond and then Pierre you’re welcome to join in here if I miss anything. But I think that clearly we may ultimately need to conduct an outcome trial but we believe that if our Phase 3 results can replicate our Trifecta Effect as we saw in Phase 2, we believe based on our discussions with key opinion leaders and high volume prescribers that CaPre could gain significant market traction without a cardiovascular trial and really become a preferred omega-3 for patients with severe hypertriglyceridemia or patients with broader cardiometabolic disease, again, even without outcome data.
boozehound3 wrote: Did you see the new seeking alpha article